Petrelintide vs Cagrilintide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicPetrelintideCagrilintide
What it is

An investigational amylin analogue, also known as ZP8396, from Zealand Pharma and Roche.1,7,8

An investigational long-acting amylin analogue from Novo Nordisk, also known as AM833.4,9

FDA status

In clinical trials

In clinical trials; not FDA-approved1,2,3

Not FDA-approved. Three Phase 3 trials, including ZUPREME-4 and ZUPREME-5, are registered on ClinicalTrials.gov.2,3,10

Is petrelintide FDA-approved?

In clinical trials

In clinical trials; not FDA-approved4,5,6

Not FDA-approved. FDA states that cagrilintide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.6

Is cagrilintide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.11

Not among the six peptides the policy lists.11

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial ZUPREME 1 (NCT06662539): a multicentre, randomized, double-blind, placebo-controlled Phase 2 trial in 485 adults with obesity, or overweight with high blood pressure or abnormal blood fats, without type 2 diabetes, followed for 42 weeks; the main result was weight change at 28 weeks.12
  • Controlled human trial Two randomized, blinded, placebo-controlled Phase 1 trials, one following participants for 16 weeks, in normal-weight, overweight or obese adults. The published abstract does not give total enrollment.8
  • Registered trial without results A Phase 2 trial in overweight or obesity with type 2 diabetes (NCT06926842), sponsored by Zealand Pharma and listed as completed in its September 9, 2026 registry record.13
  • Registered trial without results ZUPREME-5 (NCT07843472), ZUPREME-4 (NCT07843485) and a third Phase 3 trial in obesity or overweight (NCT07843498), sponsored by Roche and listed as recruiting in their October and November 2026 registry records.2,3,10

Large randomized human trials

  • Large randomized human trial A 26-week randomized Phase 2 trial comparing several cagrilintide groups in 706 adults without diabetes, with placebo and liraglutide comparison groups, published in The Lancet.9
  • Large randomized human trial REDEFINE 1, a 68-week randomized Phase 3a trial in 3,417 adults with overweight or obesity that compared the cagrilintide-semaglutide combination with each component alone and with placebo, published in The New England Journal of Medicine.14
  • Registered trial without results A Phase 3 trial of cagrilintide alone in people with overweight or obesity and type 2 diabetes (NCT07220759), listed as active, not recruiting in its August 3, 2026 registry record.5
  • Registered trial without results A Phase 3 trial of cagrilintide alone in overweight or obesity (NCT07745504), listed as not yet recruiting in its August 4, 2026 registry record.15
Records collected

9 ClinicalTrials.gov records and 2 PubMed records collected

7 ClinicalTrials.gov records and 6 PubMed records collected

Area of study

Metabolic and weight1

Metabolic and weight4

Latest dated events
  1. The retained ClinicalTrials.gov records of ZUPREME-4 and a third Phase 3 trial list them as recruiting.3,10
  2. The retained ClinicalTrials.gov record of the ZUPREME-5 Phase 3 trial lists it as recruiting.2
  3. Results of the ZUPREME 1 Phase 2 trial are published online in The Lancet Diabetes & Endocrinology.12
  1. FDA’s page on unapproved GLP-1 drugs, which says cagrilintide cannot be used in compounding, is updated, as shown by its content-current date.6
  2. REDEFINE 1 results for the cagrilintide-semaglutide combination are published in The New England Journal of Medicine.14
  3. Results of the Phase 2 cagrilintide trial are published in The Lancet.9

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Petrelintide With Enicepatide in Adults With Obesity or Overweight · record history version 3 · last update posted 2026-07-07 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  2. 2
    ClinicalTrials.gov record NCT07843472 · retained source version 2026-10-07:b4d7f3eecf4b6c9a8842198319f5d5c3a421bf03ca09434d4d315fdacfc97697 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026

  3. 3
    ClinicalTrials.gov record NCT07843485 · retained source version 2026-11-05:e5fd0540362d59efc4e0e476ab3f05c74427735d5576cee67cbafed4c6f394d5 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026

  4. 4
    Cagrilintide and CagriSema in Children and Adolescents With Excess Body Weight · record history version 5 · last update posted 2026-07-17 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  5. 5
    ClinicalTrials.gov record NCT07220759 · retained source version 2026-08-03:50fb10a6adbd81022c8cc1ee950e283b46f97533acbf5a944399ee4e77eaceb1 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  6. 6
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  7. 7
    ClinicalTrials.gov record NCT06662539 · retained source version 2026-03-23:25a9d8533efb66766440e5abf5b03342f70235dae33ae71a773e757bb8847402 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  8. 8
    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials (2026) · PMID 42017294 ↗

    Diabetes, Obesity and Metabolism · Official source · Source checked November 14, 2026

  9. 9
    Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial (2021) · PMID 34798060 ↗

    The Lancet · Official source · Source checked November 14, 2026

  10. 10
    ClinicalTrials.gov record NCT07843498 · retained source version 2026-11-05:9b532d149aaffed6b38bd85ef1731c2342003d62a19554586ffc692016cb1e62 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026

  11. 11
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  12. 12
    Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial (2026) · PMID 42810355 ↗

    The Lancet Diabetes & Endocrinology · Official source · Source checked November 16, 2026

  13. 13
    ClinicalTrials.gov record NCT06926842 · retained source version 2026-09-09:66566db76c0ba35707f571957d43a26bb1a34c1cb277263d2109ca1fdebaf137 ↗

    ClinicalTrials.gov · Official source · Source checked September 9, 2026

  14. 14
    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1, 2025) · PMID 40544433 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  15. 15
    ClinicalTrials.gov record NCT07745504 · retained source version 2026-08-04:624035118e08abe47d4c56faae694b0047f077f295c17f9043520d41dcfc3f70 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026